S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Buy THIS stock before Taiwan is attacked (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Urgent Warning (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Urgent Warning (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Buy THIS stock before Taiwan is attacked (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Urgent Warning (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Urgent Warning (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Buy THIS stock before Taiwan is attacked (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Urgent Warning (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Urgent Warning (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Buy THIS stock before Taiwan is attacked (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Urgent Warning (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Urgent Warning (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:APVO

Aptevo Therapeutics - APVO Stock Forecast, Price & News

$2.04
+0.02 (+0.99%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.95
▼
$2.10
50-Day Range
$1.74
▼
$2.44
52-Week Range
$1.65
▼
$7.20
Volume
175,208 shs
Average Volume
76,718 shs
Market Capitalization
$10.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
537.3% Upside
$13.00 Price Target
Short Interest
Healthy
2.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.34mentions of Aptevo Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($6.58) to ($6.87) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

921st out of 1,009 stocks

Pharmaceutical Preparations Industry

450th out of 494 stocks

See Top Rated MarketRank™ Stocks Here

APVO stock logo

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Stock News Headlines

March 30, 2023 | finance.yahoo.com
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
March 30, 2023 | finance.yahoo.com
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
March 31, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
January 9, 2023 | finance.yahoo.com
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
December 20, 2022 | finance.yahoo.com
Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate
December 14, 2022 | benzinga.com
Short Volatility Alert: Aptevo Therapeutic
December 12, 2022 | finance.yahoo.com
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)
November 10, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
March 31, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
November 9, 2022 | finance.yahoo.com
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
November 3, 2022 | finance.yahoo.com
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
October 1, 2022 | seekingalpha.com
APVO Aptevo Therapeutics Inc.
September 19, 2022 | finance.yahoo.com
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND
August 11, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 4, 2022 | nasdaq.com
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
June 17, 2022 | msn.com
Aptevo Therapeutics's Return On Capital Employed Overview
June 11, 2022 | seekingalpha.com
Aptevo gains after disclosing additional remission data in leukemia trial
June 9, 2022 | finance.yahoo.com
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
May 12, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
April 12, 2022 | finanznachrichten.de
Aptevo Therapeutics: APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
April 12, 2022 | finance.yahoo.com
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
March 30, 2022 | morningstar.com
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Morningstar
March 29, 2022 | finance.yahoo.com
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
March 24, 2022 | benzinga.com
Aptevo Therapeutics: Q4 Earnings Insights
March 24, 2022 | seekingalpha.com
Aptevo climbs as 2021 revenue more than doubles
March 24, 2022 | msn.com
Why Did Aptevo Therapeutics Stock Jump 25% Today?
March 24, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Company Calendar

Last Earnings
3/24/2022
Today
3/30/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
CUSIP
N/A
CIK
1671584
Web
www.aptevotherapeutics.com
Phone
(206) 838-0500
Fax
206-838-0503
Employees
54
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+537.3%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,460,000.00
Net Margins
N/A
Pretax Margin
82.31%
Return on Equity
-370.26%
Return on Assets
-73.38%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
3.16
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$12.29 million
Price / Sales
0.84
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
8.16

Miscellaneous

Outstanding Shares
5,090,000
Free Float
4,883,000
Market Cap
$10.38 million
Optionable
Optionable
Beta
5.31

Social Links


Key Executives

  • Marvin L. White
    President, Chief Executive Officer & Director
  • Jeffrey G. Lamothe
    Chief Operating Officer & Executive Vice President
  • Daphne L. Taylor
    Chief Financial Officer & Senior Vice President
  • Scott C. Stromatt
    Chief Medical Officer & SVP-Clinical Development
  • SoYoung Kwon
    Senior VP-Human Resources & Corporate Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













APVO Stock - Frequently Asked Questions

What is Aptevo Therapeutics' stock price forecast for 2023?

0 brokerages have issued 12 month price objectives for Aptevo Therapeutics' shares. Their APVO share price forecasts range from $13.00 to $13.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 537.3% from the stock's current price.
View analysts price targets for APVO or view top-rated stocks among Wall Street analysts.

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 on January 1st, 2023. Since then, APVO stock has decreased by 12.1% and is now trading at $2.04.
View the best growth stocks for 2023 here.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 105,200 shares, a decrease of 30.1% from the February 28th total of 150,400 shares. Based on an average daily volume of 91,100 shares, the short-interest ratio is presently 1.2 days.
View Aptevo Therapeutics' Short Interest.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our APVO earnings forecast.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its quarterly earnings results on Thursday, March, 24th. The biotechnology company reported ($1.27) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.25%), Morgan Stanley (0.22%), Bank of Montreal Can (0.20%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $2.04.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $10.38 million and generates $12.29 million in revenue each year.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 3/31/2023 by MarketBeat.com Staff